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Breast tumors in (FVB × BALB-NeuT) F1 mice have characteristic loss of chromosome 4 and sporadic loss or gain
of other chromosomes. We employed the Illumina GoldenGate genotyping platform to quantitate loss of
heterozygosity (LOH) across the genome of primary tumors, revealing strong biases favoring chromosome 4
alleles from the FVB parent. While allelic bias was not observed on other chromosomes, many tumors showed
concerted LOH (C-LOH) of all alleles of one or the other parent on sporadic chromosomes, a pattern consistent
with cytogenetic observations. Surprisingly, comparison of LOH in tumor samples relative to normal unaffected
tissues from these animals revealed significant variegated (stochastic) deviations from heterozygosity (V-LOH) in
every tumor genome. Sequence analysis showed expected changes in the allelic frequency of single nucleotide
polymorphisms (SNPs) in cases of C-LOH. However, no evidence of LOH due to mutations, small deletions, or
gene conversion at the affected SNPs or surrounding DNA was found at loci with V-LOH. Postulating an epigenetic
mechanism contributing to V-LOH, we tested whether methylation of template DNA impacts allele detection
efficiency using synthetic oligonucleotide templates in an assay mimicking the GoldenGate genotyping format.
Methylated templates were systematically over-scored, suggesting that the observed patterns of V-LOH may
represent extensive epigenetic DNA modifications across the tumor genomes. As most of the SNPs queried do
not contain standard (CpG) methylation targets, we propose that widespread, non-canonical DNA modifications
occur during Her2/neuT-driven tumorigenesis.
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Genetic instability is a key characteristic of most advanced cancers as
they progress toward increasingly malignant phenotypes [1]. Genetic
instability also complicates the long-term success of conventional
chemotherapies, target-specific therapies, as well as newer cancer
vaccine strategies, as genetic diversity within tumor cell populations
allows for multiple mutant phenotypes to be acquired and exist in
dynamic genetic and epigenetic landscapes [2,3].
Mouse models of cancer provide important insights into the
biology of spontaneous cancer development [4,5]. Using inbred
animals, stages of tumor development can be followed under
reproducible, controlled circumstances allowing dissection of regula-
tory checkpoints that are overcome as tumors emerge. These models
also provide experimental systems for evaluating strategies for cancer
therapy [6–8]. Whereas tumors are sometimes cured in mice,
translation of the same strategies to human patients has been less
effective [9–11].
One limitation of inbred experimental tumor models is their
inability to account for genetic events that generate populations of
phenotypically distinct cells on the assortment of alleles among
mitotic progeny. Loss of heterozygosity (LOH) is a common
characteristic of human cancers [12–14], but the importance of
mechanisms leading to LOH in tumor evolution in humans is
primarily investigated once tumors are already established [15,16].
Mechanisms leading to tumor development influenced by LOH are
underappreciated in most mouse models as LOH is masked in
inbred animals.
Nonetheless, several studies have used F1 intercrosses between two
inbred mouse strains to demonstrate patterns of LOH. Early studies
were interpreted as evidence for selective loss of tumor suppressor
genes [17–19]. Most of these studies used low-resolution mapping of
tumor genotypes with microsatellite and single nucleotide polymor-
phism (SNP) typing and, thus, provided a limited view of genetic
instability in the emerging tumors. Major genetic instability on
mouse chromosome 4 has been observed repeatedly using these
methods, as have minor patterns of LOH on other chromosomes
[20,21].
In the present study, we used a medium density genotyping
bead array to evaluate the assortment of alleles in spontaneous
breast tumors emerging in genetically identical FVB × BALB-
NeuT F1 female mice. The array is capable of determining the
genotypes of up to 32 DNA samples simultaneously; parental
alleles differ at 553 polymorphic SNPs, representing every
chromosome of the mouse genome. Using an internally matched
set of normal samples as reference, we quantified LOH for each
heterozygous SNP in each tumor sample. Two patterns of LOH
were revealed, one in which the same parental allele was poorly
represented for most or all SNPs along a given chromosome. This
concerted LOH (C-LOH) was validated by sequencing genomic
regions around several SNPs using DNA from individual tumors.
A second, unexpected pattern of LOH (variegated) was also
revealed. These regions of the tumor genomes were found to have
remained heterozygous (i.e., mirroring the germline). As genotyp-
ing interrogates regions of naked DNA flanking each SNP, we
present data to suggest that genome-wide epigenetic events were
detected by this assay in the F1 tumor genomes. As such, this
experimental approach provides a new method for evaluating
genetic and environmental variables regulating somatic genetic
changes in evolving tumors.Materials and Methods
Mice
Hemizygous BALB/c-neuT mice were originally acquired from
Dr Guido Forni [7,22] and were maintained by intercross with
transgene negative BALB/c female littermates such that all transgene-
positive animals contained a single copy of the mouse mammary
tumor virus promoter–driven neuT transgene. The presence of the
transgene was monitored using DNA primers (gtaacacaggcagatgtagga
and actggtgatgtcggcgatat) in a standard polymerase chain reaction
(PCR) assay. F1 hybrid mice were from matings of neuT
transgene-positive BALB/c males with wild-type FVB/J females.
Only female progeny were used in this study. Low-fat diet (LFD) and
high-fat diet (HFD) were from Research Diets (New Brunswick, NJ)
(D12450H and D12451) and introduced at weaning.
Tumor Incidence and Recovery of Tumors and Other Tissues
Animals were monitored weekly for the appearance of
palpable tumors. All animals developed multiple tumors (≥5
of 10 glands affected). Tumors were excised from each of the
F1 mice when any one tumor exceeded 100 mm2 (width ×
length). Other tissues (tail, ear, liver, lung, and kidney) were
free of visible tumor nodules and were excised as sources of
reference DNAs.DNA Preparation and Analysis
DNA was extracted from the tumors and reference tissues
using DNAeasy (Qiagen, Venlo, Netherlands) according to the
manufacturer’s procedures.
Genotyping and Statistical Analyses
DNA samples from normal tissue (ear, liver, kidney, and tail) and
breast tumors of FVB × BALB-NeuT F1 mice were used for
genotyping using the GoldenGate Bead Array by the Mayo Clinic
Genotyping Core of the Medical Genomics Facility according to the
manufacturer’s recommendations (Illumina, Inc, San Diego, CA).
The mouse MD linkage panel used contains ~1600 mouse SNPs,
~550 of which were found empirically to be heterozygous in normal
tissue from our F1 mice. There was some difference in the reported
genotypes for FVB and BALB/c relative to the animals used in our
study, and we excluded SNPs from the analysis when one allele was
not detected with at least 33% intensity of the other allele in the
reference tissues. Raw data files were processed using GenomeStudio
software (Illumina, Inc). From these data, we extracted measurements
of LOH by first computing z-scores ([value − meannormal]/standard
deviationnormal) indicating the deviation from the average value from
normal tissue for each of the genotyped SNPs. We tested for
significant differences in these z-scores between normal and tumor
samples using two-sample rank-sum tests for individual SNPs across
the entire genome, and also for each chromosome for each tumor by
calculating the average z-score on a given chromosome. Z-scores were
compared between the 21 tumor samples and the seven normal tissues
used in the analysis (see Supplemental Tables 1 and 2). DNA from one
tumor sample (a 22nd) was excluded for technical reasons following
DNA isolation, and an eighth normal tissue sample was excluded in
some cases on the basis of being a significant outlier (more than 5 SD
outside the tight cluster of the other samples). Heat maps in Figure 2
summarize analyses both including and excluding this outlier normal
sample. TwoDNA samples, one normal reference and one tumor, were
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this platform. The concordance correlation coefficients were 0.706 and
0.943, respectively. Parallel statistical assessments including this outlier
yielded the same overall conclusions, but the variance of the normal
samples was substantially distorted by including this sample.
PCR Amplification and Sequence Validation of Tumor
Genotype Calls
We used the BALB genome to guide the design of oligonucleotide
primers that would amplify approximately 2 kb of genomic
DNA flanking SNP gnf04.123.467 on chromosome 4 (forward
primer: 5′-TGGACACTTTGCCCCTTCTTAGAAT-3′ and re-
verse primer: 5′-TTCCATTTTCCATTTCATAAATGAGG-3′)
and CEL-15_9687257 on chromosome 15 (forward primer:
5′-CACTGTGCTGCCTTTGACAAGGATTC-3′ and reverse
primer: 5′-CTTTGGCAGATAAAGTTTGCACGACC-3′). Geno-
mic DNA used previously for genotyping assay was amplified with
Phusion Hot Start DNA Polymerase according to the manufacturer’s
recommendations (New England BioLabs, Ipswich, MA). PCR
products were resolved by agarose gel electrophoresis, purified, and
subjected to Sanger sequencing.
In Vitro SNP Detection and Impact of Modified
DNA Templates
A “GG-in-a-tube” assay was developed on the basis of the workflow
diagrams of the GoldenGate Genotyping Assay and known genomic
sequences around SNP CEL-15_9687257 on mouse chromosome
15. Synthetic FVB.0 template (5′-GATATACATGCATACTGAGA
CTCAGTGGACAGAGAAAGCAGAAGCTTTCTAGC-3′), and
BALB.0 template (5′-GATATACATGCATACTGAGACTCAG
TAGAC*AGAGAAAGC*AGAAGCTTTCTAGC-3′), wild-type
or internally substituted (at the *) 5-methyl- or 5-hydroxymethyl-
deoxycytosine templates, were obtained from Integrated DNA
Technologies Inc (Coralville, IA). Allele-specific and locus-
specific primers with added tags for post-annealing amplification
were designed based on the manufacturer’s (Illumina, Inc) application
notes as follows: FVB–allele-specific oligonucleotide (ASO)
5 ′ - A C T T C G T C A G T A A C G G A C G C T A G A A A G
CTTCTGCTTTCTCTGTCC-3′; BALB-ASO 5′-ACTTCGTCAGT
AACGGACGCTAGAAAGCTTCTGCTTTCTCTGTCT-3′; locus-
specific oligonucleotide (LSO) 5′-CTGAGTCTCAGTATGCATGTA
TATCAGTCCGAACCTGCCTATGATTCGGTCTGCCTATAGT
GAGTC-3′; universal P1 primer 5′-ACTTCGTCAGTAACGGAC-3′;
universal P3 primer 5′-GACTCACTATAGGCAGAC-3′. Regions
shown underlined correspond to genomic sequences around the SNP.
FVB.0 (5 ng) and BALB.0 (25 ng) or modified BALB templates were
mixed together in thin-walled PCR tubes with a standardized mixture of
FVB-ASO (10 pmol), BALB-ASO (100 pmol), and LSO (10 pmol)
primers inQuick Solution buffer, 2.5UPfuUltra polymerase (Stratagene,
LaJolla, CA), and deoxynucleoside triphosphates (Roche, Mannheim,
Germany). The reactions were placed in a thermocycler programmed for
one cycle: 95°C for 1 minute, 55°C for 1 minute, and 68°C for 15
minutes to anneal and extend the primers. After quick clean-up (Qiagen),
the reaction products were ligated using T4 ligase according to the rapid
ligation protocol (Invitrogen, Carlsbad, CA) and then used directly for 20
cycles of PCR amplification with P1/P3 primers and Hi-Fidelity
polymerase (Roche). Amplification products were resolved by agarose
gel electrophoresis, excised, purified (Qiagen), and sequenced using the
P3 primer.Results
Spontaneous Breast Tumors Emerging in Heterozygotes Have
Patterns of Cytogenetic Diversity and Extensive LOH in the F1
Tumor Genomes
Female heterozygous FVB × BALB-NeuT F1 mice expressing
activated ErbB2 (neu) oncogene under transcriptional control of the
mouse mammary tumor virus promoter were monitored weekly for
spontaneous tumor development. All animals developed multiple
tumors that were palpable by approximately 13 weeks of age. Tumors
for study were harvested when any one tumor reached 100 mm2.
Spectral karyotyping (SKY) showed changes in chromosome number,
deletions, and translocations (Supplemental Figure 1). Loss of
chromosome 4 or other aberrations involving the fourth chromosome
was a common feature in these tumors (100/100 mitotic figures from
10 different animals). No chromosome 4 alterations were observed in
mitotic spreads of normal heterozygous fibroblasts.
The genomes of F1 tumors were surveyed for LOH using genomic
DNA purified from F1 tumors and F1 normal tissues (GoldenGate
Genotyping Assay; Illumina, Inc). There are 553 SNPs represented
on the mouse medium density array that distinguish FVB/J from
BALB/c mice. An overview of SNP genotype allele frequencies for 8
normal and 21 tumor genomes is shown in Figure 1B. For nearly
every individual SNP across the genome, the allelic ratios of the
samples were clustered at 0.5 as expected for an F1 genetic cross.
However, closer inspection of the data revealed that the tumor allele
frequencies were much more varied compared to the allele frequencies
of the normal tissue DNA samples from the same animals.
To evaluate the tumor allele frequencies more closely, a
heterozygosity score was defined operationally for each assay using
the mean score empirically established for each SNP using DNA of
normal tissue isolated from the F1 animals. Deviation from this mean
value was then calculated using a z-score ([value − meannormal]/
standard deviationnormal) for each tumor and normal DNA sample
(summarized in Supplemental Table 1). Negative z-scores were
defined to signify under-representation of the BALB/c allele and
positive scores were defined to signify under-representation of the
FVB allele. Support for directional loss of LOH was only evident on
chromosome 4 (Supplemental Table 2). While the genotyping calls
for individual SNPs on chromosomes 8, 11, 12, and 18 were
suggestive of skewing toward one allele or the other, this trend was
not supported in a follow-up study. However, the strong bias toward
loss of BALB/c alleles on chromosome 4 was consistently observed.
The degree of SNP heterozygosity was visualized using the
calculated z-scores. A threshold of 2.0 in absolute value was used to
score LOH, and the results of the individual SNP calls were displayed
for each tumor and normal sample in a heat map (Figure 2; gray,
heterozygous; white, apparent loss of FVB allele; black, apparent loss
of BALB/c allele). Two versions of this heat map are shown, as
genotyping data from one of the normal tissue samples displayed
many allelic ratios outside the otherwise tight cluster of normal.
Similar results were found with or without this outlier in the analysis.
These data revealed extensive LOH throughout the genomes of the
tumor samples; 96% of the SNPs shown had undergone LOH in at
least 1 of the 21 tumor samples studied. There was concerted loss of
the same allele (concerted or “C-LOH”) at adjacent SNPs on
chromosome 4 for nearly all tumors. Most often, the C-LOH on
chromosome 4 was a loss of BALB alleles, suggesting an allelic bias in
whatever mechanism results in loss of chromosome 4. Some tumors
Figure 1. DNA samples from F1 tumors (N = 21) and F1 normal tissues (N = 7) were assessed for heterozygosity using the GoldenGate
Assay (Illumina, Inc). The expected frequency of alleles is 0.5. The range of 2 SDs around the mean z-score at each heterozygous SNP is
shown chromosome by chromosome. SNPs with a median empirical allele frequency score between 0.75 and 0.25 were selected for
further analysis (see below).
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centromeres was noted, indicating that somatic crossing over was not
likely a major contributor to tumorigenesis in this model. A portionFigure 2. Extensive LOH in primary F1 breast tumors. Allelic ratios for
on the degree of deviation from the average allele intensities for the no
chromosomes for tumors (N = 21) if the SNP z-score is N2 SDs o
apparent loss of FVB SNP, z-score N 2; black, apparent loss of BALB/c
based on analysis including an apparent outlier normal sample (N
calculations based on data omitting that outlier. While the overall res
throughout the genomes of the tumors.of the observed patterns of LOH is consistent with the deletions and
duplications of chromosomes seen in our cytogenetic analysis.
However, many of the measured events in the array analysis dideach SNP in each tumor sample were converted to z-scores based
rmal tissue DNAs. SNPs are shown color-coded across each of the
utside of heterozygous measurements of normal tissues (white,
SNP, z-score b−2; gray, retained heterozygosity). (A) Calculations
5 SDs outside the other samples) from tumor-bearing mice; (B)
ults are similar, this approach reveals additional positions of LOH
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Figure 3. C-LOH on chromosome 4 validated by sequence analysis. (A) Enlargement of heat map from Figure 2, box indicates SNP
gnf04.123.367 used for Sanger sequence analysis. Only samples shown in B and C are numbered; arrows point to tumors. (B)
Sequencing chromatograms focusing on nucleotide polymorphism and shown for three tumors and three normal tissues from (BALB/
c-neuT × FVB) F1 mice. Lines represent allelic measurements (A, solid line—BALB allele; C, dashed line—FVB allele). (C) Allelic ratios
from genotype array for gnf04.123.367, represented as z-scores for normal and tumor DNA samples (negative z-score represents loss of
BALB allele). Arrows indicate samples whose sequence chromatograms are shown in B.
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(“V-LOH”) in which one locus exhibited loss of one parental allele,
whereas a linked SNP had loss of the opposite allele. A second
independent analysis of 16 additional tumors (including analysis of
two tumors from the same mouse) and 6 normal tissues revealed the
same patterns (not shown). Independent tumors recovered from the
same animals (upper left vs lower right quadrants) displayed unrelated
patterns of LOH (not shown).
LOH at Chromosome 4 Represents Chromosome Loss
The allelic skewing of the genotypes on chromosome 4 suggested
that gross gains or losses of genetic information had occurred at loci
across this chromosome, a hypothesis supported by cytogenetic
analysis (Figure 1). To verify that genotyping in this manner can be
used to visualize a true loss of one of the parental alleles, we identified
genomic sequences for both parent strains around one of the SNPs on
chromosome 4 (gnf04_123.367; Figure 3A) and used PCR to amplify
approximately 2 kb of genome from the same tumor and normal
DNA used for genotyping. Sanger sequencing revealed allelic ratios in
genomic DNA (Figure 3). Both BALB and FVB alleles were presentin DNA sequenced (Figure 3B) from tumor samples scored as
heterozygous by genotyping (gray in Figure 3A; absolute z-score b 2
in Figure 3C) such as tumor 23. In contrast, in DNA from samples
such as tumor 8 (white in Figure 3A; z-score ~ 14, Figure 3C) and
tumor 16 (black in Figure 3A; z-score ~ −37, Figure 3C), one of the
alleles was dominant by both sequencing and genotyping. A similar
analysis of SNPs on chromosome 12 validated that the genotyping
approach was also sensitive to copy number changes in individual
tumors displaying C-LOH at a second genomic location (not shown).
Detection of a Second Pattern of LOH Indicates Another
Mechanism(s) at Play
The V-LOH pattern observed by genotyping individual tumors
was surprising in that it was widespread yet seemingly distributed
stochastically in any given tumor. To determine whether the V-LOH
was also caused by physical loss or gain of genomic DNA, we repeated
the PCR and sequencing approach, choosing SNPs at locations where
both C-LOH and V-LOH were apparent among different tumor
samples (Figure 4). For example, tumor 13 (arrow in Figure 4A)
displayed C-LOH across chromosome 15 and analysis of SNP
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V-LOH compared in B and C. (B) Chromatograms focusing on the nucleotide polymorphism (A—BALB allele; G—FVB allele; note that the
empirical measure of heterozygosity for this SNP is not of equal intensities of the A and G nucleotide peaks). (C) Allelic ratios from
genotype array for CEL-15_9687257, represented as z-scores for normal and tumor DNA samples (positive z-score represents loss of FVB
or gain of BALB allele). Arrows indicate samples whose sequence chromatograms are shown in B and additional samples having aberrant
genotype calls in patterns of V-LOH that were also heterozygous by sequence analysis (not shown).
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(Figure 4B). In contrast, sequence analysis of tumor 16 displaying a
strong V-LOH measurement found SNP to be heterozygous,
indistinguishable from the normal unaffected tissue. This finding
was consistent, even in cases where the genotyping call of the V-LOH
sample was quantitatively more extreme than the same SNP for
another tumor in the same set displaying C-LOH (genotype
quantitations expressed as z-scores; Figure 4C). Moreover, sequence
analysis revealed no evidence for additional mutations, rearrange-
ments, or deletions in the vicinity of the SNPs analyzed in
these tumors.
The V-LOH appears to be fundamentally different from the
C-LOH, indicating two different underlying mechanisms. This
conclusion is supported by quantitation of the allelic ratios in the
sequence analysis and comparing those ratios to the genotyping
quantitation (z-scores) of tumor and normal samples. Figure 5 shows
the tumor-to-normal ratios, calculated from analyses of six different
SNPs using DNA from 26 independent tumors plotted versus the
z-scores for the same samples. The data for C-LOH and V-LOH
are displayed separately and show the clear correlation of allelic ratios
detected by sequence analysis and bead array in cases of C-LOH (top
panel; R2 = 0.6783; P = .0016). Despite multiple examples of SNPsexhibiting high deviation in allelic ratios by bead array genotyping,
the sampled examples of V-LOH showed no correlation between
genotype ratios and allelic ratios determined by direct sequencing
(bottom panel; R2 = 0.0057; P = .73).
Influence of Dietary Fat on Developing Breast Cancer
and V-LOH
A major advantage for using genotyping to study genomic LOH
events in tumors is that a variety of preventative and therapeutic
interventions can be easily assessed on individual animal tumors
simultaneously. As a first test, we investigated whether dietary
modification in breast cancer–prone F1 mice altered tumor LOH
patterns. Animals were fed either defined low-fat or high-fat chow
beginning at weaning. Tumor development was monitored until all
mice developed breast tumors. In mice fed the LFD, tumor onset was
delayed by 1 week, resulting in a commensurate 1-week difference in
the timing of sacrifice due to tumor burden (median survival: HFD,
16 weeks; LFD, 17 weeks; hazard ratio = 2.62; P = .0023
Mantel-Cox; n = 46 per group). Tumors from mice receiving HFD
(n = 11) and LFD (n = 8) were genotyped as before, along with
normal tissue samples from the same animals. Diet appeared to have
little influence on loss of chromosome 4, the bias toward preferential
Figure 5. C-LOH but not V-LOH correlates with quantitative
genotyping. Peak height ratios were calculated from Sanger
sequence chromatograms for tumor (n = 26) and normal (n =
10) DNA samples. SNP peak height ratios for tumor samples were
normalized to the average peak height ratio for normal tissue DNA
and are shown as a function of genotype array z-scores for those
tumor samples. Top panel: Combined analysis of four different
SNPs found in patterns of C-LOH. Bottom panel: Combined
analysis of four different SNPs found in patterns of V-LOH.
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Figure 6. V-LOH in tumor genotype influenced by dietary fat in
FVB × BALB-NeuT F1 mice. Heterozygous animals were assigned
to an HFD or LFD at weaning. Genotyping data from breast tumor
DNA samples were analyzed as before. The absolute z-scores are
shown for SNP CEL-15_9687257 for individual tumors where
V-LOH on chromosome 15 was observed. Absolute z-scores for
normal tissues did not differ by diet group and are shown
combined. Lines indicate the median values for each group.
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as visualized by C-LOH (not shown). However, lowering the fat
content of the diet decreased the percentage of SNPs in a V-LOH
context by approximately half. To test for any quantitative effect on
the genotyping assay, we compared the absolute z-scores for SNP
CEL-15_9687257 in tumor DNA from individual mice fed with
HFD or LFD (Figure 6). The tumors from HFD-fed mice had
significantly higher median deviations from normal (z-scores) than
did tumors from LFD-fed mice (P = .028, Kruskal-Wallis test; HFD
vs LFD, P b .05, Dunn’s multiple comparison test). Whether the
delay in tumor development is related to the drop in V-LOH is not
known. However, because C-LOH appears similar in tumors from
the two diet groups, this possibility is attractive and needs further
investigation.Methyl- and Hydroxymethylcytosines Near the SNP Can
Disrupt Template-Assisted Ligation-Based Genotyping
Several factors point to an epigenetic etiology of the V-LOH
pattern in these primary breast tumors: the retention of allelic
frequencies where V-LOH is observed, the absence of mutations, the
widespread distribution of V-LOH throughout the tumor genomes,
and the finding that environmental changes can influence the pattern.
Epigenetic modifications to DNA play key regulatory roles in
developmental processes, and altered patterns of CpG methylation
have been described in a variety of cancer settings [2]. We reasoned
that epigenetic DNA modifications in tumors compared to normal
tissue DNA might interfere with the mechanics of the GoldenGate
genotyping assay. In this approach to SNP detection, approximately
50 nt region of native DNA around the polymorphism is interrogated
by allele-specific probes. These probes compete for annealing to the
targeted area. The annealed product is extended and ligated to an
adjacent locus-identifying probe; the final product is amplified for
detection. The output is thus a measure of the efficiency of these
annealing, extension, and ligation reactions.
To test the hypothesis that modifications to the target DNA might
influence SNP detection efficiency, we developed an in vitro version
of the assay (outlined in Figure 7A). Instead of genomic DNA, we
substituted synthetic, methylation-free or methylcytosine- or hydro-
xymethylcytosine-containing templates corresponding to SNP
CEL-15_9687257 (studied in Figure 4). Unmodified templates
containing either the BALB (A) or FVB (G) allele were synthesized.
Figure 7B shows that BALB/FVB heterozygosity can be measured
using a mixture of control templates (top chromatogram). The
AB
Figure 7. Efficiency of SNP genotyping assay affected by the presence of non-canonical DNA methylation. (A) Synthetic single-stranded
templates were used in an in vitro assay involving competitive annealing of ASO probes (3′ T or C colored gray) followed by extension and
ligation to an LSO probe. A wild-type FVB template was used for all reactions and mixed with an unmodified BALB template (shown) or
templates synthesized to contain one or two 5-methylcytosines or 5-hydroxymethylcytosines (locations indicated by C*). The reactions
create a new strand that is amplified and sequenced (B) to reveal how template strandmodification affected ASO-dependent allelic ratios.
Results shown are from one of three independent experiments; statistics are for the pooled data.
Neoplasia Vol. 17, No. 4, 2015 Widespread Non-Canonical Epigenetic Modifications Felts et al. 355BALB:FVB allelic ratio was increased when the BALB target DNA
contained modified cytosines (P b .0001). As the presence of
methylcytosine can increase the local Tm of DNA [23], we infer that
our estimates of heterozygosity are substantially altered when one
allelic template is modified. As the SNPs we examined in our
experiments are not found in or near CpG islands and as 75% to 80%
of the genomic sequences adjacent to the SNP loci probed by the
genotyping assay contain no CG dinucleotides, we propose that
non-canonical epigenetic modifications may be more widespread in
cancers than previously shown.
Discussion
Understanding the mechanisms contributing to the genetic hetero-
geneity of cancers remains a key to our ability to prevent and treat this
multifaceted disease [24]. Animal models remain an important tool
for cancer researchers as they often provide insights into fundamental
properties of cellular transformation and malignant evolution [4]. We
have developed a new approach using F1 heterozygous progeny from
two inbred strains and quantitative genotyping measurements to
simultaneously measure gross chromosomal changes and epigenetic
modification of the cancer genome. This approach allows evaluation
of contributive factors and provides a platform for testing intervention
strategies in cancerous tissues.
In the Her2/neu oncogene model used in this study, deletions or
losses of chromosome 4 is strongly associated with tumorigenesis, as
all the tumors examined had this phenotype in both the inbred (not
shown) and heterozygous F1 mouse lines. Cytogenetic analysisshowed no example of trisomy at chromosome 4 and a loss of
chromosome 4 was favored. Loss of chromosome 4 is one of the most
common events in mouse tumor models [17–19,25]. However, the
reasons for this are still unknown. Our genotyping approach readily
detected a strong preference for the loss of the BALB/c fourth
chromosome in FVB × BALB-NeuT F1 mice, similar to that
observed in other studies of F1 studies with neuT animals [18]. In our
study, sporadic loss of the FVB chromosome was observed in roughly
10% of the analyzed tumors. Whether this pervasive monoploidy is a
fundamental step in tumor development or is consequential to an
inherent instability of chromosome 4 remains to be determined.
Our unexpected finding that genetic regions marked by SNPs
throughout the genome are modified at a high frequency in breast
cancers could be an important clue for understanding how this cancer
develops. We raise the possibility that a dysregulation of DNA-
modifying machinery is a critical step in promoting tumor growth.
Stepwise changes in DNA methylation have been shown to be linked
to breast epithelial cell transformation in vitro [26], and differences in
methylation may define human breast cancer subtypes [27,28].
Epigenetic modifications to DNA can alter DNA repair mechanisms
as well as change gene expression programs leading to further gains or
losses of encoded traits [29–31]. In heterozygous cells where allelic
diversity in gene function is pervasive, silencing or activation of
cellular functions can occur through an epigenetic mechanism with a
single hit changing expression of only one of the parental genes.
While most of the events measured in our study appear to be silent
with respect to allelic preference (no evidence of selection), the sheer
356 Widespread Non-Canonical Epigenetic Modifications Felts et al. Neoplasia Vol. 17, No. 4, 2015number of these events increases the likelihood that relevant genes
will be affected, providing an opportunity for the evolution of gene
expression profiles favoring uncontrolled growth.
An unexpected finding was the extensive LOH in 2 of 14 normal
F1 reference samples (one of which can be seen in Figure 2). Each
tissue sample was free of tumor by visual inspection. In fact, in these
studies where no evidence of metastasis to any organ in the mice
studied, these normal tissues also retained heterozygous signatures of
SNPs on chromosome 4. It appears, therefore, that DNA from these
cancer-prone animals contains some level of epigenetic modification,
perhaps providing fertile ground for subsequent transformational or
metastatic events. The events driving LOH in normal tissues remain
to be elucidated.
The plasticity of genome in cancer has implications for the design
of effective strategies to treat tumors. Most cancer models use inbred
mice. As humans are an outbred population characterized by
genome-wide heterozygosity, the behavior of cancers might be
modeled more closely by heterozygous animals. We have shown that
tumors driven by the Her2/neu oncogene contain both chromosomal
losses and other patterns of allelic imbalances that appear to be
epigenetically driven. Reducing the fat in the diets of the animals led
to a measurable delay in tumor onset and mortality in the hybrid mice
and an apparent decrease in V-LOH throughout the genome. These
observations suggest that genetic instability might be modifiable and
that F1 models may be advantageous for evaluating certain
interventions. Therapeutic interventions, especially those designed
to target specific cellular molecules, likely kill cells within a
heterogeneous tumor with varying effectiveness. Testing and linking
the assortment of functional traits to allele-specific events using F1
animals has the potential to elucidate mechanisms of tumor resistance
under therapeutic pressure. This would be particularly true when a
therapy targets a single allele.
The chemical nature of the epigenetic changes visualized in our
study is not known. A substantial portion of the SNPs we assayed is
devoid of CpG dinucleotides, suggesting that another epigenetic
mechanism(s) is in play in our F1 breast tumors. Cytosine
methylation is the predominant modification to eukaryotic genomic
DNA and, until recently, thought to be restricted to CpG sequence
contexts [32,33]. The presence of non-CpG cytosine methylation has
been documented in embryonic and multipotent stem cells [30].
More recently, Guo et al. [34] showed that non-CG methylation
regulates neuronal function in a region of the adult mouse brain
associated with regeneration potential, suggesting that this form of
DNA modification correlates with cellular plasticity. How pervasive
other modification patterns are throughout the tumor genomes
remains to be tested, but certainly our experiments show that
methylated cytosine can contribute to some of the LOH signals.
However, canonical CpG methylation cannot be the whole story.
How DNA modifications function during tumor evolution, and to
what extent they can be controlled by conventional therapies, by new
targeted therapies or by lifestyle choices remains to be determined in
future studies.
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